We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Chemo Doublets Should Be Standard Treatment for Advanced NSCLC

Jun 1, 2002
Volume: 
11
Issue: 
6
  • Lung Cancer

ASCO—A new study from the Cancer and Leukemia Group B (CALGB 9730) shows
that chemotherapy doublets should be the standard treatment for advanced
non-small-cell lung cancer (NSCLC), Rogerio C. Lilenbaum, MD, reported at the
38th Annual Meeting of the American Society of Clinical Oncology (abstract 2).

"Not only did the results show an increase in response rate but, more
importantly, an increase in survival time in patients who received carboplatin
[Paraplatin] and paclitaxel [Taxol], compared with paclitaxel alone,"
said Dr. Lilenbaum, director of the Thoracic Oncology Program, Mount Sinai
Comprehensive Cancer Center, Miami Beach.

The phase III trial randomized 584 patients (561 evaluable) with stage IIIB/IV NSCLC to receive paclitaxel 225
mg/m² given over 3 hours on day 1 with
or without carboplatin to AUC 6 every 3 weeks for up to six cycles. The
patients had received no prior chemotherapy.

The median patient age was 63.5 years; 155 (27%) were 70 years of age or
older, and 99 (18%) were performance status (PS) 2 on the ECOG scale. Quality
of life was assessed at baseline, 2, 6, 9, and 12 months, using the EORTC
QLQ-C30 and QLQ-LC13 questionnaires.

The objective response rate was 29% in patients on combination therapy vs
17% in those on paclitaxel alone (P < .0001), Dr. Lilenbaum said.

With a median follow-up of 19.7 months, median overall survival was 8.8
months with the combination vs 6.7 months with single-agent therapy, a 24%
relative increase in survival for those receiving carboplatin/paclitaxel.
Failure-free survival was also significantly longer with combination therapy—4.6
months vs 2.5 months for single-agent therapy.

One-year survival, at 37% for the combination vs 33% for the single agent,
was not significantly different. This may be due, in part, to a higher use of
second-line therapy in the single-agent arm (39% vs 32%) and of platinum-based
combinations in particular (14% vs 7%), Dr. Lilenbaum said.

Pages

  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »

Related Articles

  • Epacadostat/Durvalumab Combo Well Tolerated in Solid Tumor Trial
  • Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
  • Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung Cancer
  • New Option in NSCLC With IL-15 Agonist Plus Immune Checkpoint Inhibition
  • Durable Responses, Longer Survival Seen in NSCLC With Nivolumab at 5 Years

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.